Are you a print subscriber? Activate your account. By Garett Sloane - 2 hours 35 min ago By Gillian Follett - 2 hours 35 min ago By E.J. Schultz - 2 hours 35 min ago By Jack Neff - 2 hours 35 min ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer ...

Guggenheim lowered the firm’s price target on Merck (MRK) to $130 from $137 and keeps a Buy rating on the shares. While noting shares are down about 2.6% since the company reported Q3 earnings last ...

The pharmaceutical company posted revenue of $16.66 billion in the period, also topping Street forecasts. Six analysts surveyed by Zacks expected $16.55 billion. Merck expects full-year earnings in ...

Shares of Merck & Co. Inc. MRK inched 0.44% higher to $101.17 Thursday, on what proved to be an all-around mixed trading ...

BofA analyst Charlie Yang lowered the firm’s price target on Merck (MRK) to $120 from $140 and keeps a Buy rating on the shares. Q3 ...

Oct 17 (Reuters) - German science and technology group Merck (MRCG.DE), opens new tab is open to more acquisitions for its Life Science business after announcing in May it would buy Mirus Bio for ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...